homepage-top-section

Enbumyst is approved by the US Food and Drug Administration (FDA) for treating oedema linked to congestive heart failure, hepatic, and renal diseases in adults. The agreement will

This makes Palynziq the only enzyme substitution therapy that received approval to reduce blood phenylalanine (Phe) concentrations in individuals with PKU. The approval follows data from PEGASUS, a

FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes

Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered

The partnership brings together a high-titre glutamine synthetase (GS) knockout (−/−) Chinese hamster ovary (CHO) cell line solution, free from additional intellectual property costs, aiming to streamline the

These facilities will integrate advanced manufacturing technologies and AI for supporting production of the company’s obesity and next-generation neuroscience medications. Construction is scheduled to commence in spring 2026,

This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes and facilitate the delivery of scientifically validated, partner-ready therapeutic candidates. It will combine Syngene’s

The collaboration will combine Mayo Clinic’s Platform architecture and clinical-genomic datasets with MSD’s virtual cell technologies to improve target identification, drive early development decisions, and enhance disease understanding.

The placement was led by existing investor BVF Partners and joined by entities such as Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional